تخطَّ إلى المحتوى
PipDig
EUR/USDLoading…GBP/USDLoading…USD/JPYLoading…XAU/USDLoading…BTC/USDLoading…

Forex News

Sernova and Seraxis to merge as BetaNova Biotherapeutics

Sernova Biotherapeutics and Seraxis Holdings plan a merger into BetaNova Biotherapeutics, with closing expected in November 2026.

بقلم Omar Al-Farsi, MENA Markets EditorPipDig
  • Sernova Biotherapeutics signed the merger agreement on September 8, 2026.
  • The combined company will be called BetaNova Biotherapeutics.
  • The merger is expected to close in November 2026.

Merger

Sernova Biotherapeutics and Seraxis Holdings proposed a merger into BetaNova Biotherapeutics. The merger agreement was dated September 8, 2026.

Extreme close-up of two overlapping glass droplets on a glossy surface whose reflections create interlocking circular shapes in cool blue-green tones, softly focused with a low-contrast empty lower third.
Sernova and Seraxis to merge as BetaNova Biotherapeutics

The closing is expected in November 2026.

Companies

Sernova Biotherapeutics is associated with the Cell Pouch Bio-hybrid Organ. BetaNova Biotherapeutics is focused on T1D islet cell replacement.

Seraxis Holdings, Inc. is tied to the SR-02 and SR-03 stem cell-derived pancreatic islet programs. Jonathan Rigby is President and CEO of Sernova, and Will Rust, Ph.D., is President and CEO of Seraxis.

Conference

Sernova Biotherapeutics is set to take part in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1, 2026.

المصدر: GlobeNewswire,